Meeting Overview - The annual general meeting of Zhejiang Dayang Biological Technology Group Co., Ltd. was held on May 15, 2025, with both on-site and online voting options available [1][2] - A total of 99 shareholders participated, representing 22,354,962 shares, which is 26.6130% of the total shares [1] Voting Participation - On-site attendance included 23 shareholders, representing 21,442,357 shares, or 25.5266% of total shares [1] - Online voting involved 76 shareholders, representing 912,605 shares, or 1.0864% of total shares [2] - Among the participating small and medium investors, 88 individuals voted, representing 2,602,291 shares, or 3.0980% of total shares [2] Resolutions Passed - The meeting approved the following resolutions: 1. The annual board work report for 2024 was presented and approved [3] 2. The annual supervisory board report for 2024 was presented and approved [3] 3. The 2024 annual report and its summary were approved [3] 4. The estimated daily related transactions for 2025 and confirmation of 2024 transactions were approved, with 111,100 shares opposed, representing 3.4560% of votes [3] 5. The annual financial settlement report for 2024 was approved [4] 6. The financial budget report for 2025 was approved [4] 7. The reappointment of Zhonghui Certified Public Accountants as the auditing firm for 2025 was approved, with an audit fee of 800,000 yuan [4] 8. The profit distribution plan for 2024 was approved, proposing a cash dividend of 3.00 yuan per 10 shares, with 994,070 shares excluded from the total [5] 9. The confirmation of the remuneration for directors and supervisors for 2024 was approved [6] 10. The remuneration scheme for directors and supervisors was approved [6] 11. The financing and guarantee proposal for the company and its subsidiaries was approved, allowing for bank financing up to 600 million yuan and guarantees up to 300 million yuan [7] Legal Opinion - The legal opinion provided by Shanghai Jintiancheng Law Firm confirmed that the meeting's procedures and voting were in compliance with relevant laws and regulations [7]
大洋生物: 浙江大洋生物科技集团股份有限公司2024年年度股东大会决议公告